Eyepoint Pharmaceuticals (EYPT) revenue breakdown
By product, License and Collaboration Agreement is the largest at 53% of fiscal 2025 revenue; Royalty Income grew fastest, 33% a year over 9 years.
By region, Country US is the largest at 96% of fiscal 2025 revenue, growing 39% a year over 9 years.
Revenue by product
Fiscal years, as Eyepoint Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $31M.
| Products | 2017 | 2018 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Collaboration Agreement | $7M | $1M | — | $1M | $12M | $756,000 | $362,000 | $31M | $38M | $17M | 53% |
| Royalty Income | $970,000 | $2M | $2M | $2M | $2M | $871,000 | $1M | $989,000 | $2M | $13M | 42% |
| Product sales, net | — | — | — | $17M | $21M | $35M | $40M | $14M | $3M | $2M | 5% |
| Collaborative Research and Development | — | — | $3M | — | — | — | — | — | — | — | — |
| Collaborative Research and Development | — | — | — | — | — | $60,000 | — | — | — | — | — |
Revenue by region
Fiscal years, as Eyepoint Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $31M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Country US | $2M | $7M | $3M | $19M | $23M | $36M | $40M | $45M | $42M | $30M | 96% |
| China | — | — | — | $1M | $12M | $851,000 | $823,000 | $648,000 | $1M | $1M | 4% |
| UNITED KINGDOM | $100,000 | $100,000 | $100,000 | $100,000 | $100,000 | $100,000 | $100,000 | $100,000 | $100,000 | $100,000 | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for EYPT.
Open EYPT in InvestinglyQuestions
Where does Eyepoint Pharmaceuticals make its money?
In fiscal 2025, by product: License and Collaboration Agreement $17M, Royalty Income $13M, Product sales, net $2M.
From Eyepoint Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.